Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea

/PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing...

Related Keywords

Australia ,Taiwan ,Shanghai ,China ,United States ,United Kingdom ,Singapore ,Canada ,South Korea ,Switzerland ,Chinese ,South Korean ,Great Britain ,Asia Pacific ,Sacituzumab Govitecan ,Kerry Blanchard ,Cancer Association ,Drug Administration ,Gilead Sciences Inc ,Prnewswire Everest Medicines Limited ,Health Sciences Authority ,China National Medical Products Administration ,European Union ,Ministry Of Food ,Medicines Limited ,Drug Safety ,New Drug Application ,Fast Track Designation ,Orphan Drug Designation ,Chief Executive Officer ,Triple Negative Breast Cancer ,Rare Severe Disease Priority Review Designation ,Taiwan Food ,Gilead Sciences ,Everest Medicines ,Greater China ,Southeast Asian ,Standardized Diagnosis ,Advanced Breast Cancer ,Breast Cancer Expert Committee ,National Cancer Control Center ,Breast Cancer Professional Committee ,Chinese Anti Cancer Association ,Chinese Anti Cancer ,